CAI vs NEO: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CAI and NEO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CAI and NEO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Caris Life Sciences, Inc. is an Irving, Texas based precision-medicine company that sequences tumors and blood to guide cancer treatment. Its core service is comprehensive molecular profiling: the MI Profile platform runs whole exome and whole transcriptome sequencing on tissue, while the Caris Assure platform does blood-based profiling, and newer assays extend into whole genome sequencing, minimal residual disease monitoring (Caris WGS MRD), hematologic profiling (Caris ChromoSeq) and multi-cancer early detection (Caris Detect). Alongside the clinical lab business, Caris licenses access to its multi-modal molecular and clinical database and runs research services for pharmaceutical partners, which is the second revenue line and the reason the company describes itself as an AI or TechBio company rather than a lab.

Full CAI guide

NeoGenomics, Inc. (Nasdaq: NEO) operates a national network of CLIA-certified, CAP-accredited laboratories that perform cancer genetics testing, plus a full-service sample-processing lab in Cambridge, United Kingdom. Its customers are community oncology and pathology practices, hospital pathology labs, academic centers and pharmaceutical companies, and its menu spans older modalities such as FISH, IHC and PCR alongside next-generation sequencing panels and molecular residual disease testing through the RaDaR franchise. Management reports the company as a single segment with roughly 2,500 employees, and clinical testing supplies the large majority of revenue, with pharma and advanced diagnostics work making up the smaller remainder. Anthony Zook took over as chief executive and has been reorganizing the commercial effort, including a dedicated pathology and oncology sales team launched during 2026.

Full NEO guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CAI drivers: Reimbursement-driven pricing (ASP); Volume growth and the shift to blood.
• NEO drivers: Mix shift into NGS carries the revenue line; Margin discipline turning into real adjusted EBITDA.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The clearest risk is reimbursement: a large share of recent revenue growth came from price rather than volume, and coverage decisions, rate resets, or payer pushback could reverse that quickly. For NEO, gAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $53 million and no positive price-to-earnings ratio to anchor valuation.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CAI if you believe its drivers more; NEO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CAI and NEO guides.

CAI. Caris has no meaningful earnings multiple because it is only now reaching breakeven on a GAAP basis, so the market prices it on sales and on the durability of the pricing gains behind them. At roughly 5 times trailing revenue the stock is far below where it traded shortly after the June 2025 IPO, when the 52-week high reached ~$42.50 against a recent ~$16 price. Gross margin has widened toward the mid-60s percent range from the high-40s a year earlier, which is the other half of why losses collapsed.

NEO. With no trailing earnings, sales and adjusted EBITDA multiples do most of the work here: roughly 2.7 times trailing revenue and roughly 40 times the midpoint of guided 2026 adjusted EBITDA. That second figure only looks reasonable if margin expansion continues for several more years, which is the crux of the debate on the name. Balance sheet context matters too, since cash and short-term investments of about $146 million sit against roughly $385 million of convertible principal ($69.0M of 0.25% notes due 2028 and $316.3M of 0.75% notes due 2032), and the shares have ranged from $5.94 to $16.92 over the past 52 weeks.

Headline figures (approximate, August 2026): CAI shows revenue (ttm) ~$907M (+~100% YoY), q1 2026 revenue ~$216M (+~79% YoY), 2026 revenue guidance ~$1.00B to $1.02B (+~23% to 26%), q1 2026 adjusted ebitda ~$26M (fourth straight positive quarter); NEO shows revenue (ttm) ~$766M (four quarters ended June 30, 2026), q2 2026 revenue ~$202M, up ~11% year over year, market cap ~$2.1B (~$16 per share on ~128.5M shares), price to sales ~2.7x trailing; enterprise value ~$2.3B, or ~3.0x sales.

CAI and NEO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CAI and NEO exposure against your real portfolio. It is not an investment adviser.